US Patent

US11602513 — Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Method of Use · Assigned to Flamel Ireland Ltd · Expires 2037-07-21 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects modified release formulations of gamma-hydroxybutyrate with improved dissolution and pharmacokinetic properties.

USPTO Abstract

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Drugs covered by this patent

sodium-oxybate (SODIUM OXYBATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3576`	—	sodium-oxybate
`U-3576`	—	sodium-oxybate
`U-3576`	—	sodium-oxybate
`U-3576`	—	sodium-oxybate

Patent Metadata

Patent number: US11602513
Jurisdiction: US
Classification: Method of Use
Expires: 2037-07-21
Drug substance claim: No
Drug product claim: No
Assignee: Flamel Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.